Birinapant

SI-5082

Birinapant, >98% (HPLC)

CAS No. : [1260251-31-7]

MDL No. : MFCD25976869

Synonyms : TL-32711

IUPAC Name : (2S,2'S)-N,N'-((2S,2'S)-((3S,3'S,5R,5'R)-((6,6'-difluoro-1H,1'H-[2,2'-biindole]-3,3'-diyl)bis(methylene))bis(3-hydroxypyrrolidine-5,1-diyl))bis(1-oxobutane-1,2-diyl))bis(2-(methylamino)propanamide)

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
250MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
500MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
1G	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : Birinapant is a bivalent Smac mimetic. A potent antagonist for XIAP and cIAP1 with Kds of 45 nM and less than 1 nM, respectively. Birinapant induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.

References : Allensworth J. L. et al. Breast Cancer Res Treat., 137(2), 359-371, 2013;
Krepler C. et al. Clin Cancer Res.,19(7):1784-1794, 2013; Nguyen Q. D. et al.: Clin Cancer Res., 19(14), 3914-3924, 2013; Benetatos C. A. et al.: Mol Cancer Ther., 13(4), 867-879, 2014.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.